| Business Summary | | Embrex,
Inc.
develops
and
markets
biological
delivery
technology
and
biological
products
to
increase
the
productivity
and
profitability
of
the
global
poultry
industry.
Embrex
has
developed
and
commercialized
the
Inovoject
system,
a
proprietary,
automated
in-the-egg
injection
system
that
can
inoculate
20,000
to
50,000
eggs
per
hour
and
eliminates
the
need
for
manual,
post-hatch
injection
of
certain
vaccines.
In
addition
to
the
Inovoject
system,
Embrex
has
developed
and
is
marketing
its
Viral
Neutralizing
Factor
(VNF)
technology,
useful
in
the
development
of
certain
avian
vaccines.
The
Company
also
has
developed
and
is
marketing
Bursaplex,
a
VNF-based
vaccine
for
protection
against
avian
infectious
bursal
disease
(IBD).
Embrex
also
is
developing
various
other
proprietary
pharmaceutical
and
biological
products
to
improve
bird
health,
reduce
bird
production
costs
and
provide
other
economic
benefits
to
the
poultry
industry. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Embrex,
Inc.
develops
and
markets
biological
delivery
technology
and
biological
products
to
increase
the
productivity
and
profitability
of
the
global
poultry
industry.
For
the
six
months
ended
6/30/01,
revenues
rose
14%
to
$21.6
million.
Net
income
rose
26%
to
$4
million.
Revenues
reflect
additional
installations
of
Inovoject(R)
systems
and
increased
injection
activity.
Higher
income
also
reflects
a
change
in
product
mix
and
higher
operating
efficiencies. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Peter Holzer, 55 Chairman | -- | -- | Randall Marcuson, 52 Pres,
CEO and Directtor | $410K | $473K | Don Seaquist, 52 VP
of Fin. and Admin. | 245K | -- | Brian Cosgriff, 48 VP
of Sales and Marketing | 230K | 197K | David Baines, Ph.D., 53 VP
of Global Marketing and Sales | 214K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|